Be the first to like this
Rheumatoid Arthritis (RA) is a common rheumatological disorder. Many drugs including Anti TNF agents have been used for the treatment of this condition. The result hitherto, have been excellent, but shortcomings and the absence of complete remissions even in Anti TNF treated patients, makes the trial of newer agents, targeted to novel pathophysiologic molecules, all the more important and urgent. New insights in the pathogens of RA and three new biologics for RA have been discussed.